<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p3" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_3{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_3{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_3{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_3{left:341px;bottom:30px;}
#t5_3{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_3{left:377px;bottom:30px;}
#t7_3{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_3{left:540px;bottom:30px;}
#t9_3{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_3{left:996px;bottom:873px;letter-spacing:-0.1px;}
#tb_3{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#tc_3{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#td_3{left:857px;bottom:768px;letter-spacing:0.07px;word-spacing:0.07px;}
#te_3{left:987px;bottom:768px;letter-spacing:0.15px;}
#tf_3{left:857px;bottom:748px;letter-spacing:0.15px;}
#tg_3{left:857px;bottom:728px;letter-spacing:0.12px;}
#th_3{left:857px;bottom:708px;letter-spacing:0.12px;}
#ti_3{left:857px;bottom:689px;letter-spacing:0.15px;}
#tj_3{left:857px;bottom:660px;letter-spacing:0.15px;}
#tk_3{left:857px;bottom:640px;letter-spacing:0.13px;}
#tl_3{left:857px;bottom:620px;letter-spacing:0.13px;}
#tm_3{left:944px;bottom:620px;}
#tn_3{left:857px;bottom:591px;letter-spacing:0.17px;}
#to_3{left:857px;bottom:571px;letter-spacing:0.17px;}
#tp_3{left:967px;bottom:571px;letter-spacing:0.16px;}
#tq_3{left:857px;bottom:551px;letter-spacing:0.11px;word-spacing:0.04px;}
#tr_3{left:857px;bottom:531px;letter-spacing:0.14px;}
#ts_3{left:857px;bottom:502px;letter-spacing:0.15px;}
#tt_3{left:895px;bottom:502px;letter-spacing:0.16px;}
#tu_3{left:857px;bottom:482px;letter-spacing:0.17px;}
#tv_3{left:857px;bottom:453px;letter-spacing:0.16px;}
#tw_3{left:857px;bottom:434px;letter-spacing:0.15px;}
#tx_3{left:857px;bottom:414px;letter-spacing:0.15px;}
#ty_3{left:857px;bottom:385px;letter-spacing:0.15px;}
#tz_3{left:895px;bottom:385px;letter-spacing:0.16px;}
#t10_3{left:36px;bottom:778px;letter-spacing:-0.1px;}
#t11_3{left:36px;bottom:760px;letter-spacing:-0.09px;}
#t12_3{left:36px;bottom:723px;letter-spacing:-0.13px;word-spacing:-0.02px;}
#t13_3{left:36px;bottom:705px;letter-spacing:-0.09px;}
#t14_3{left:36px;bottom:687px;letter-spacing:-0.1px;}
#t15_3{left:36px;bottom:668px;letter-spacing:-0.09px;}
#t16_3{left:36px;bottom:650px;letter-spacing:-0.13px;word-spacing:0.03px;}
#t17_3{left:36px;bottom:632px;letter-spacing:-0.1px;}
#t18_3{left:36px;bottom:613px;letter-spacing:-0.1px;}
#t19_3{left:36px;bottom:595px;letter-spacing:-0.1px;word-spacing:-0.05px;}
#t1a_3{left:36px;bottom:577px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t1b_3{left:36px;bottom:558px;letter-spacing:-0.09px;}
#t1c_3{left:36px;bottom:540px;letter-spacing:-0.12px;word-spacing:-0.07px;}
#t1d_3{left:36px;bottom:522px;letter-spacing:-0.11px;word-spacing:-0.07px;}
#t1e_3{left:36px;bottom:503px;letter-spacing:-0.15px;word-spacing:-0.1px;}
#t1f_3{left:36px;bottom:485px;letter-spacing:-0.13px;word-spacing:-0.1px;}
#t1g_3{left:36px;bottom:467px;letter-spacing:-0.09px;}
#t1h_3{left:36px;bottom:448px;letter-spacing:-0.12px;word-spacing:-0.07px;}
#t1i_3{left:36px;bottom:430px;letter-spacing:-0.1px;word-spacing:-0.07px;}
#t1j_3{left:36px;bottom:412px;letter-spacing:-0.1px;}
#t1k_3{left:36px;bottom:393px;letter-spacing:-0.1px;}
#t1l_3{left:36px;bottom:375px;letter-spacing:-0.09px;}
#t1m_3{left:36px;bottom:357px;letter-spacing:-0.09px;}
#t1n_3{left:36px;bottom:338px;letter-spacing:-0.14px;word-spacing:-0.02px;}
#t1o_3{left:36px;bottom:320px;letter-spacing:-0.11px;word-spacing:-0.03px;}
#t1p_3{left:36px;bottom:302px;letter-spacing:-0.09px;}
#t1q_3{left:36px;bottom:283px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t1r_3{left:36px;bottom:247px;letter-spacing:-0.17px;word-spacing:0.08px;}
#t1s_3{left:36px;bottom:210px;letter-spacing:-0.09px;}
#t1t_3{left:44px;bottom:153px;letter-spacing:-0.1px;}
#t1u_3{left:211px;bottom:162px;}
#t1v_3{left:223px;bottom:153px;letter-spacing:-0.09px;}
#t1w_3{left:44px;bottom:133px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1x_3{left:44px;bottom:113px;letter-spacing:-0.09px;word-spacing:-0.02px;}
#t1y_3{left:888px;bottom:121px;}
#t1z_3{left:900px;bottom:113px;letter-spacing:-0.13px;}
#t20_3{left:954px;bottom:121px;}
#t21_3{left:961px;bottom:113px;letter-spacing:-0.09px;}
#t22_3{left:44px;bottom:93px;letter-spacing:-0.09px;}
#t23_3{left:44px;bottom:72px;letter-spacing:-0.26px;}
#t24_3{left:569px;bottom:81px;}
#t25_3{left:576px;bottom:72px;letter-spacing:-0.25px;word-spacing:-0.11px;}
#t26_3{left:44px;bottom:52px;letter-spacing:-0.09px;}
#t27_3{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_3{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_3{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_3{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_3{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s4_3{font-size:18px;font-family:Arial-BoldMT_5te;color:#ED1D24;}
.s5_3{font-size:18px;font-family:ArialMT_5tg;color:#000;}
.s6_3{font-size:18px;font-family:ArialMT_5tg;color:#0065A4;}
.s7_3{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s8_3{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s9_3{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts3" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg3Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg3" style="-webkit-user-select: none;"><object width="1210" height="935" data="3/3.svg" type="image/svg+xml" id="pdf3" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_3" class="t s0_3">NCCN Guidelines Version 4.2024 </span>
<span id="t2_3" class="t s0_3">Head and Neck Cancers </span>
<span id="t3_3" class="t s1_3">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_3" class="t s2_3">® </span>
<span id="t5_3" class="t s1_3">(NCCN </span>
<span id="t6_3" class="t s2_3">® </span>
<span id="t7_3" class="t s1_3">), All rights reserved. NCCN Guidelines </span>
<span id="t8_3" class="t s2_3">® </span>
<span id="t9_3" class="t s1_3">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_3" class="t s3_3">NCCN Guidelines Index </span>
<span id="tb_3" class="t s3_3">Table of Contents </span>
<span id="tc_3" class="t s3_3">Discussion </span>
<span id="td_3" class="t s4_3">Clinical Trials: </span><span id="te_3" class="t s5_3">NCCN believes that </span>
<span id="tf_3" class="t s5_3">the best management for any patient </span>
<span id="tg_3" class="t s5_3">with cancer is in a clinical trial. </span>
<span id="th_3" class="t s5_3">Participation in clinical trials is </span>
<span id="ti_3" class="t s5_3">especially encouraged. </span>
<span id="tj_3" class="t s5_3">Find an NCCN Member Institution: </span>
<span id="tk_3" class="t s6_3">https://www.nccn.org/home/member- </span>
<span id="tl_3" class="t s6_3">institutions</span><span id="tm_3" class="t s5_3">. </span>
<span id="tn_3" class="t s4_3">NCCN Categories of Evidence and </span>
<span id="to_3" class="t s4_3">Consensus: </span><span id="tp_3" class="t s5_3">All recommendations </span>
<span id="tq_3" class="t s5_3">are category 2A unless otherwise </span>
<span id="tr_3" class="t s5_3">indicated. </span>
<span id="ts_3" class="t s5_3">See </span><span id="tt_3" class="t s6_3">NCCN Categories of Evidence </span>
<span id="tu_3" class="t s6_3">and Consensus. </span>
<span id="tv_3" class="t s4_3">NCCN Categories of Preference: </span>
<span id="tw_3" class="t s5_3">All recommendations are considered </span>
<span id="tx_3" class="t s5_3">appropriate. </span>
<span id="ty_3" class="t s5_3">See </span><span id="tz_3" class="t s6_3">NCCN Categories of Preference. </span>
<span id="t10_3" class="t s3_3">NCCN Head and Neck Cancers Panel Members </span>
<span id="t11_3" class="t s3_3">Summary of the Guidelines Updates </span>
<span id="t12_3" class="t s3_3">Multidisciplinary Team and Support Services (TEAM-1) </span>
<span id="t13_3" class="t s3_3">Cancer of the Oral Cavity (Including Mucosal Lip) (OR-1) </span>
<span id="t14_3" class="t s3_3">Cancer of the Oropharynx (ORPH-1) </span>
<span id="t15_3" class="t s3_3">• p16-negative (ORPH-2) </span>
<span id="t16_3" class="t s3_3">• p16 (HPV)-positive (ORPHPV-1) </span>
<span id="t17_3" class="t s3_3">Cancer of the Hypopharynx (HYPO-1) </span>
<span id="t18_3" class="t s3_3">Cancer of the Nasopharynx (NASO-1) </span>
<span id="t19_3" class="t s3_3">• Systemic Therapy for Nasopharyngeal Cancers (NASO-B) </span>
<span id="t1a_3" class="t s3_3">Cancer of the Glottic Larynx (GLOT-1) </span>
<span id="t1b_3" class="t s3_3">Cancer of the Supraglottic Larynx (SUPRA-1) </span>
<span id="t1c_3" class="t s3_3">Ethmoid Sinus Tumors (ETHM-1) </span>
<span id="t1d_3" class="t s3_3">Maxillary Sinus Tumors (MAXI-1) </span>
<span id="t1e_3" class="t s3_3">Very Advanced Head and Neck Cancer (ADV-1) </span>
<span id="t1f_3" class="t s3_3">Recurrent/Persistent Very Advanced Head and Neck Cancer (ADV-3) </span>
<span id="t1g_3" class="t s3_3">Occult Primary (OCC-1) </span>
<span id="t1h_3" class="t s3_3">Salivary Gland Tumors (SALI-1) </span>
<span id="t1i_3" class="t s3_3">• Systemic Therapy for Salivary Gland Tumors (SALI-B) </span>
<span id="t1j_3" class="t s3_3">Mucosal Melanoma (MM-1) </span>
<span id="t1k_3" class="t s3_3">Follow-up Recommendations (FOLL-A) </span>
<span id="t1l_3" class="t s3_3">Principles of Imaging (IMG-A) </span>
<span id="t1m_3" class="t s3_3">Principles of Surgery (SURG-A) </span>
<span id="t1n_3" class="t s3_3">Principles of Radiation Techniques (RAD-A) </span>
<span id="t1o_3" class="t s3_3">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) </span>
<span id="t1p_3" class="t s3_3">Principles of Nutrition: Management and Supportive Care (NUTR-A) </span>
<span id="t1q_3" class="t s3_3">Principles of Oral/Dental Evaluation and Management (DENT-A) </span>
<span id="t1r_3" class="t s3_3">Staging (ST-1) </span>
<span id="t1s_3" class="t s3_3">Abbreviations (ABBR-1) </span>
<span id="t1t_3" class="t s7_3">The NCCN Guidelines </span>
<span id="t1u_3" class="t s8_3">® </span>
<span id="t1v_3" class="t s7_3">are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to </span>
<span id="t1w_3" class="t s7_3">treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual </span>
<span id="t1x_3" class="t s7_3">clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network </span>
<span id="t1y_3" class="t s8_3">® </span>
<span id="t1z_3" class="t s7_3">(NCCN </span>
<span id="t20_3" class="t s8_3">® </span>
<span id="t21_3" class="t s7_3">) makes no representations </span>
<span id="t22_3" class="t s7_3">or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN </span>
<span id="t23_3" class="t s7_3">Guidelines are copyrighted by National Comprehensive Cancer Network </span>
<span id="t24_3" class="t s8_3">® </span>
<span id="t25_3" class="t s7_3">. All rights reserved. The NCCN Guidelines and the illustrations herein may not </span>
<span id="t26_3" class="t s7_3">be reproduced in any form without the express written permission of NCCN. ©2024. </span>
<span id="t27_3" class="t s9_3">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
